Bcl-x(L) is expressed in ovarian carcinoma and modulates chemotherapy- induced apoptosis

Gynecologic Oncology

Volumn 70, Issue 3, 1998, Pages 398-403

  Liu, J Rebecca ^a   Fletcher, Bridget ^a   Page, Carmen ^a   Hu, Changzhi ^a   Nunez, Gabriel ^b   Baker, Vicki ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN BCL X; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; CARCINOMA; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; IN VITRO STUDY; METABOLISM; OVARY TUMOR; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA; CISPLATIN; FEMALE; FLOW CYTOMETRY; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031595523     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5125     Document Type: Article

References (28)

1. Nunez G, Clarke M F. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol. 4:1994;399-403.
2. Williams G T, Smith C A. Molecular regulation of apoptosis: genetic controls on cell death. Cell. 74:1993;777-779.
3. Fisher D E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
4. Raff M C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
5. Martin S J, Green D R. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol. 18:1995;137-153.
6. Thompson, CB. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
7. Miyashita T, Reed J C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
8. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
9. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 10:1996;1-15.
10. Tsujimoto Y, Cossman J, Jaffe E, Croce C M. Involvement of the bcl-2 oncogene in human follicular lymphoma. Science. 228:1985;1440-1443.
11. Vaux D L, Cory S, Adams J M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
12. Boise L H, Gonzalez-Garcia M, Postema C E, Ding L, Lindsten T, Turka L A, Mao X, Nunez G, Thompson C B. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
13. Castle V P, Heidelberger K P, Bromberg J, Ou S, Dole M, Nunez G. Expression of the apoptosis-suppressing protein Bcl-2 in neuroblastoma is associated with poor stage disease, unfavorable histology and N-myc amplification. Am J Pathol. 143:1993;1543-1550.
14. Dole M G, Nunez G, Merchant A K, Maybaum J, Rode C K, Block C A, Castle V P. Bcl-2 inhibits chemotherapy induced apoptosis in neuroblastoma. Cancer Res. 54:1994;3253-3259.
15. Dive C, Wyllie A H. Apoptosis and Cancer Chemotherapy. Cancer Chemotherapy. 1993;Blackwell, Oxford. p. 21-56.
16. Hellemans P, vanDam P A, Weyler J, vanOosterom A T, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 72:1995;354-360.
17. Bhargava V, Kell D, vandeRijn M, Warnke R A. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol. 145:1994;535-540.
18. Leek R D, Kaklamanis L, Pezzella F, Gatter K C, Harris A L. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor negative tumours and in situ cancer. Br J Cancer. 69:1994;135-139.
19. Krajewski S, Krajewska M, Shabaik A, Wang H G, Irie S, Fong L, Reed J C. Immunohistochemical analysis of in vivo patterns of Bcl-x expression. Cancer Res. 54:1994;5501-5507.
20. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer. 72:1995;1324-1329.
21. Herod J O, Eliopoulos A G, Warwick J, Niedobitek G, Young L S, Kerr D J. The prognostic significance of Bcl-2 and p-53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184.
22. Diebold M D, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U. Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinoma. Am J Clin Pathol. 105:1996;341-349.
23. L. J Immunol. 155:1995;3830-3838.
24. Oltvai Z N, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
25. Nicoletti I, Migliorati G, Pagliacci M C, Grignani F, Riccadi C. A rapid and simple method for measuring thymocytes apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:1991;271-279.
26. Pezzella F, Turley H, Kuzu I, Tungekar M F, Dunnill M S, Pierce C B, Harris A, Gatter K C, Mason D M. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med. 329:1993;690-694.
27. Silvestrini R, Veneroni S, Daidone M G, Benini E, Boracchi P, Mezzetti M, DiFronzo G, Rilke F, Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph-node negative breast cancer patients. J Natl Cancer Inst. 86:1994;499-504.
28. Olopade O I, Adeyanju M O, Safa A R, Hagos F, Mick R, Thompson C B, Recant W M. Overexpression of Bcl-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 3:1997;230-237.